FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Click Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (marketing authorization) for Motivista, a prescription digital therapeutic (PDT) indicated for the treatment of negative symptoms of schizophrenia, as an a…
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


